Epidemiology Data Slicer – Ulcerative Colitis
Epidemiology Data Slicer – Gastric Cancer
Epidemiology Data Slicer- Non-Hodgkin’s Lymphoma
Epidemiology Data Slicer – Chronic Heart Failure
DRG Epidemiology’s coverage of actinic keratosis (AK) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany…
Epidemiology Data Slicer – Multiple Sclerosis
DRG Epidemiology's coverage of atrial fibrillation comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of atrial fibrillation…
DRG Epidemiology’s coverage of fibromyalgia comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy,…
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for B-cell…
Epidemiology Data Slicer – Psoriasis
The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the…
A handful of newer disease-modifying therapies (DMTs) for multiple sclerosis (MS)—Novartis’s Mayzent, Bristol Myers Squibb’s Zeposia, Novartis’s Kesimpta, and Janssen’s Ponvory—have…
TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while newer biologics (i.e., Takeda’s…
Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…
A growing number of clinically unique immunomodulatory disease-modifying therapies (DMTs) are approved for the treatment of relapsing forms of multiple sclerosis (MS), the most prevalent form of…